Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrich Jaeger

Showing results (41-50 of 109) with videos related to

Pageof 11
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2005
Phase II study of oxaliplatin for treatment of patients with mucosa-associated lymphoid tissue lymphomaMarkus Raderer, Stefan Wöhrer, Rupert Bartsch, et al.
Pathology|September 22, 2010
Primary central nervous system lymphoma: a clinicopathological study of 75 casesMatthias Preusser, Adelheid Woehrer, Oskar Koperek, et al.
Cancers|April 23, 2022
Immunogenicity of COVID-19 Vaccinations in Hematological Patients: 6-Month Follow-Up and Evaluation of a 3rd VaccinationLorenz Schubert, Maximilian Koblischke, Lisa Schneider, et al.
Hemasphere|April 21, 2021
Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and FutureRenaud Heine, Frederick W Thielen, Marc Koopmanschap, et al.
European Journal of Clinical Investigation|May 18, 2012
Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myelomaJohanna Atamaniuk, Andreas Gleiss, Edit Porpaczy, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|January 11, 2003
Variable prognostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21) or inv(16)Birgit Kainz, Daniel Heintel, Rodrig Marculescu, et al.
European Journal of Cancer (Oxford, England : 1990)|March 19, 2016
Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14)Michael A Fridrik, Ulrich Jaeger, Andreas Petzer, et al.
Investigative Radiology|April 12, 2018
[68Ga]Ga-Pentixafor PET/MRI for CXCR4 Imaging of Chronic Lymphocytic Leukemia: Preliminary ResultsMarius E Mayerhoefer, Ulrich Jaeger, Philipp Staber, et al.
Blood Advances|March 17, 2020
Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient programGeorg Gelbenegger, Christian Schoergenhofer, Ulla Derhaschnig, et al.
Leukemia & Lymphoma|February 23, 2011
Anemia and erythropoiesis-stimulating agent administration in patients with non-Hodgkin lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisolone ± rituximab chemotherapy: results from an observational studyCorinne Haioun, Antonio Salar, Ruth Pettengell, et al.
Pageof 11

Showing results (41-50 of 109) with videos related to

Sort By:
Pageof 11
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 19, 2005
Phase II study of oxaliplatin for treatment of patients with mucosa-associated lymphoid tissue lymphomaMarkus Raderer, Stefan Wöhrer, Rupert Bartsch, et al.
Pathology|September 22, 2010
Primary central nervous system lymphoma: a clinicopathological study of 75 casesMatthias Preusser, Adelheid Woehrer, Oskar Koperek, et al.
Cancers|April 23, 2022
Immunogenicity of COVID-19 Vaccinations in Hematological Patients: 6-Month Follow-Up and Evaluation of a 3rd VaccinationLorenz Schubert, Maximilian Koblischke, Lisa Schneider, et al.
Hemasphere|April 21, 2021
Health Economic Aspects of Chimeric Antigen Receptor T-cell Therapies for Hematological Cancers: Present and FutureRenaud Heine, Frederick W Thielen, Marc Koopmanschap, et al.
European Journal of Clinical Investigation|May 18, 2012
Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myelomaJohanna Atamaniuk, Andreas Gleiss, Edit Porpaczy, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|January 11, 2003
Variable prognostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21) or inv(16)Birgit Kainz, Daniel Heintel, Rodrig Marculescu, et al.
European Journal of Cancer (Oxford, England : 1990)|March 19, 2016
Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14)Michael A Fridrik, Ulrich Jaeger, Andreas Petzer, et al.
Investigative Radiology|April 12, 2018
[68Ga]Ga-Pentixafor PET/MRI for CXCR4 Imaging of Chronic Lymphocytic Leukemia: Preliminary ResultsMarius E Mayerhoefer, Ulrich Jaeger, Philipp Staber, et al.
Blood Advances|March 17, 2020
Inhibition of complement C1s in patients with cold agglutinin disease: lessons learned from a named patient programGeorg Gelbenegger, Christian Schoergenhofer, Ulla Derhaschnig, et al.
Leukemia & Lymphoma|February 23, 2011
Anemia and erythropoiesis-stimulating agent administration in patients with non-Hodgkin lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisolone ± rituximab chemotherapy: results from an observational studyCorinne Haioun, Antonio Salar, Ruth Pettengell, et al.
Pageof 11